Showing 1341-1350 of 1969 results for "".
- Podium Introduces Artificial Intelligence Operating System Designed for Aesthetic Practiceshttps://modernaesthetics.com/news/podium-introduces-artificial-intelligence-operating-system-designed-for-aesthetic-practices/2485420/Podium has announced the launch of an artificial intelligence (AI)–driven operating system designed specifically for aesthetic practices, positioning the platform as a unified alternative to the fragmented software ecosystems common in cosmetic dermatology practices. The company describes the pro
- Dr. Sam Rizk to Present Deep Plane Facelift Technique at Final Baker Gordon Symposiumhttps://modernaesthetics.com/news/dr-sam-rizk-to-present-deep-plane-facelift-technique-at-final-baker-gordon-symposium/2485393/The Baker Gordon Plastic Surgery Symposium will hold its 60th and final gathering February 5-7 in Miami. Among the invited faculty is Dr. Sam Rizk, who will present his deep plane facelift technique, reflecting the procedure’s continued evolution toward natural, long-lasting results. Dr. R
- skinbetter science® Marks 10 Years of AlphaRet® Technology in Retinoid-AHA Skincarehttps://modernaesthetics.com/news/skinbetter-science-marks-10-years-of-alpharet-technology-in-retinoid-aha-skincare/2485358/skinbetter science® is marking the 10-year anniversary of its proprietary AlphaRet® technology, introduced in 2016 as one of the first topical skincare formulas to combine a retinoid with an alpha hydroxy acid (AHA). The combination, used in the flagship AlphaRet Overnight Cream, was designed to
- FDA Approves RHA® Dynamic Volume for Midface Augmentationhttps://modernaesthetics.com/news/fda-approves-rha-dynamic-volume-for-midface-augmentation/2485309/The US Food and Drug Administration (FDA) has approved RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and correction of age-related midface contour deficiencies in adults 22 and older, Revance and Teoxane announced.
- FDA Approves Once-Daily Oral Semaglutidehttps://modernaesthetics.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- New Peptide Serum Complements In-Office Aesthetic Treatmentshttps://modernaesthetics.com/news/new-peptide-serum-complements-in-office-aesthetic-treatments/2485257/ZO® Skin Health has introduced the Peptide Facial Refining Concentrate, an advanced at-home serum formulated to complement professional aesthetic procedures and enhance overall facial rejuvenation. The launch adds to the company’s physician-dispensed portfolio with
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://modernaesthetics.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- New Simulation Study Suggests BoNT/A Restrictions May Be Overly Conservativehttps://modernaesthetics.com/news/new-simulation-study-suggests-bonta-restrictions-may-be-overly-conservative/2485067/A large-scale, simulation-based study challenges the long-standing 4-hour restriction on post-injection activity following botulinum neurotoxin A (BoNT/A) treatment, suggesting that everyday behaviors may have minimal impact on toxin spread. The study, published in Scientific Reports, em
- Senolytic Skincare Platform Backed by First Peer-Reviewed Studyhttps://modernaesthetics.com/news/senolytic-skincare-platform-backed-by-first-peer-reviewed-study/2485088/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell–inspired approaches, has published its first peer-reviewed article in The Journal of Translational Medicine, validating the scientific basis of its proprietary skin regeneration platform. The
- FDA Clears Cutera truFlex® for Muscle Rehab, Recovery, and Post-Surgical Usehttps://modernaesthetics.com/news/fda-clears-cutera-truflex-for-muscle-rehab-recovery-and-post-surgical-use/2485023/Cutera, Inc. has announced that its truFlex® muscle stimulation system has received expanded US Food and Drug Administration (FDA) clearances for use in rehabilitation, recovery, and muscle wellness applications. Originally cleared for aesthetic body contouring, the system can now be used to stre